drugset / Trial / NCT06295796

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

NCT06295796

Phase 1 Completed 18 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study.

Timeline

Start
2024-06-20
Primary completion
2025-01-31
Completion
2025-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-8527 Small molecule Oral